

Haematologica
HAEMATOL/2018/201897
Version 1

To what extent can mathematical modeling inform the design of clinical trials? The example of safe dose reduction of tyrosine kinase inhibitors in responding patients with chronic myeloid leukemia

Joshua T. Schiffer and Charles A. Schiffer

Disclosures: None.

Contributions: All authors equally contributed.